FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – Europe 05/2024”.
The Monitor is a month-to-month printed overview of enterprise capital traits within the European Healthcare & Life Sciences sector.
As of the tip of Could 2025 we recognized the next present VC traits in Europe:
- Complete Healthcare & Life Sciences funding reached EUR 5,149m (+26% vs. 2024)
- Biotech/Pharma obtained 36% of the full funding quantity (EUR 1,886m) with metabolic issues (together with Diabetes, Weight problems) being the main indication (28%)
- In Could, Azafaros (Netherlands) secured the highest transaction quantity with EUR 132m, adopted by GlycoEra (Switzerland) with EUR 115m and CellCentric (Nice Britain) with EUR 106m
- GV (United States) is probably the most lively investor (by deal quantity in 2025), adopted by Alphabet (United States) and Thrive Capital (United States)
To entry the complete report, please click on right here.
By Mathias Klozenbücher and Johannes Hyperlink